Duke vaccine extends survival for patients with deadly brain cancers

A new vaccine added to standard therapy appears to offer a survival advantage for patients suffering from glioblastoma (GBM), the most deadly form of brain cancer, according to a study from researchers at Duke University Medical Center and The University of Texas MD Anderson Cancer Center.

Read the whole article on Physorg

More from Physorg